- Home
- PINC vs BEAM Comparison
PINC vs BEAM Comparison
Compare PINC & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINC
- BEAM
- Stock Information
- Founded
- PINC 2013
- BEAM 2017
- Country
- PINC United States
- BEAM United States
- Employees
- PINC N/A
- BEAM N/A
- Industry
- PINC Other Consumer Services
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PINC Consumer Discretionary
- BEAM Health Care
- Exchange
- PINC Nasdaq
- BEAM Nasdaq
- Market Cap
- PINC 1.9B
- BEAM 1.9B
- IPO Year
- PINC 2013
- BEAM 2020
- Fundamental
- Price
- PINC $21.32
- BEAM $24.55
- Analyst Decision
- PINC Hold
- BEAM Buy
- Analyst Count
- PINC 7
- BEAM 10
- Target Price
- PINC $21.42
- BEAM $47.67
- AVG Volume (30 Days)
- PINC 1.1M
- BEAM 1.1M
- Earning Date
- PINC 02-03-2025
- BEAM 02-25-2025
- Dividend Yield
- PINC 3.96%
- BEAM N/A
- EPS Growth
- PINC N/A
- BEAM N/A
- EPS
- PINC 1.32
- BEAM N/A
- Revenue
- PINC $1,325,477,000.00
- BEAM $349,643,000.00
- Revenue This Year
- PINC N/A
- BEAM N/A
- Revenue Next Year
- PINC $1.78
- BEAM $10.82
- P/E Ratio
- PINC $15.78
- BEAM N/A
- Revenue Growth
- PINC 2.65
- BEAM 328.73
- 52 Week Low
- PINC $17.96
- BEAM $20.84
- 52 Week High
- PINC $23.56
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- PINC 41.40
- BEAM 41.52
- Support Level
- PINC $20.96
- BEAM $24.96
- Resistance Level
- PINC $21.98
- BEAM $29.52
- Average True Range (ATR)
- PINC 0.49
- BEAM 1.64
- MACD
- PINC -0.06
- BEAM -0.50
- Stochastic Oscillator
- PINC 19.56
- BEAM 11.02
About PINC Premier Inc.
Premier Inc is a Charlotte, North Carolina-based technology-driven healthcare improvement company, uniting an alliance of United States (U.S.) hospitals, health systems, and other providers and organizations to transform healthcare. The company's revenue is all sourced domestically and is reported in two business segments: the supply chain services and the consulting and technology platform of performance services. It generates the majority of its revenue from the supply chain services segment.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.